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Background: The strict and demanding dietary treatment and mild cognitive abnormalities seen in PKU treated
from a young age can be expected to affect the health-related quality of life (HRQoL) of patients and their families.
Our aim was to describe the HRQoL of patients with PKU from a large international study, using generic HRQoL
measures and an innovative PKU-specific HRQoL questionnaire (PKU-QOL). Analyses were exploratory, performed
post-hoc on data collected primarily to validate the PKU-QOL.
Methods: A multicentre, prospective, non-interventional, observational study conducted in France, Germany, Italy,
The Netherlands, Spain, Turkey and the UK. Patients diagnosed with PKU aged ≥9 years old and treated with a
Phe-restricted diet and/or Phe-free amino acid protein supplements and/or pharmacological therapy were included
in the study; parents of at least one patient with PKU aged <18 years were also included. HRQoL was assessed by
generic measures (Pediatric Quality-of-Life Inventory; Medical Outcome Survey 36 item Short Form; Child Health
Questionnaire 28 item Parent Form) and the newly developed PKU-QOL. Mean generic domain scores were
interpreted using published reference values from the general population. PKU-QOL domain scores were described
overall and in different subgroups of patients defined according to severity of PKU, overall assessment of patient’s
health status by the investigator and treatment with tetrahydrobiopterin (BH4).
Results: Data from 559 subjects were analysed: 306 patients (92 children, 110 adolescents, 104 adults) and 253
parents. Mean domain scores of generic measures in the study were comparable to the general population. The
highest PKU-QOL impact scores (indicating greater impact) were for emotional impact of PKU, anxiety about blood
Phe levels, guilt regarding poor adherence to dietary restrictions or Phe-free amino acid supplement intake and
anxiety regarding blood Phe levels during pregnancy. Patients with mild/moderate PKU and those receiving BH4
reported lower practical and emotional impacts of the diet and Phe-free amino acid supplement intake.
Conclusion: Patients with PKU showed good HRQoL in the study, both with the generic and PKU-specific measures.
Negative impacts of PKU on a patient’s life, including the emotional impact of PKU and its management, was
delineated by the PKU-QOLs across all age groups.
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Phenylketonuria (PKU; MIM 261600) is a rare inherited
disorder of phenylalanine (Phe) metabolism caused by a
deficiency of the enzyme phenylalanine hydroxylase
(PAH; EC 1.14.16.1). In the absence or deficiency of
PAH, the essential amino acid phenylalanine cannot be
sufficiently hydroxylated to tyrosine (Tyr). This results
in increased blood concentrations of Phe and toxic ac-
cumulation in the brain. Untreated PKU results in
severe intellectual disability and neurological abnormal-
ities [1]. The incidence in Europe is estimated to be
1:10.000 [2].
The implementation of neonatal screening programs
in the 1960s enabled early diagnosis and initiation of
treatment for PKU, thus successfully preventing mental
disability. Treatment for PKU includes a life-long diet
restricted in Phe that is supported nutritionally with a
Phe-free amino acid supplement (i.e., medical food,
metabolic formula, amino acid mixtures). Maintaining
low blood Phe levels by strict adherence to the diet is
the strongest determinant for a good cognitive outcome
[1, 3, 4].
However, the management of PKU is complex and can
be burdensome. A Phe-restricted diet excludes many
foods naturally high in protein (such as dairy products,
meat, fish, eggs and bread) and the Phe-free amino acid
supplements required for nutritional completeness of
the diet are considered unpalatable by many patients.
Additionally, specialty low-protein foods necessary for
adequate quantity and variety of food within the very re-
stricted diet may be poorly accepted and create a finan-
cial burden. Adherence to diet therapy is essential,
especially during early childhood years, but is often
problematic and an association of the diet with adverse
feeding behaviours in young patients has been reported
[5–8]. Recent and ongoing development of pharmaco-
logical treatments may allow modification of dietary re-
striction in some patients, but do not yet consistently
allow discontinuation of traditional diet therapy.
While patients treated continuously from an early age
generally have a favourable outcome with normal overall
development, subtle abnormalities have been demon-
strated [9].
The IQ of patients treated from an early age has been
demonstrated to be within the normal range but below
the population mean [10], and executive function defi-
cits, associated with concurrent high blood Phe levels,
are observed in both children (who suffer the strongest
effect as demonstrated in a meta-analysis [11] and
adults [12–16]. Furthermore, high blood Phe levels
were demonstrated to have a direct negative effect on
mood in a crossover, double-blind placebo-controlled
study that used the Profile of Mood States (POMS)
questionnaire [16].Both the strict and demanding therapy and the mild
cognitive abnormalities seen in PKU treated from an
early age can be expected to affect the quality of life of
patients and their families. However, studies evaluating
the Health Related Quality of Life (HRQoL) of patients
with PKU have demonstrated an HRQoL comparable to
that of the general population [17–20], with the excep-
tion of a lower HRQoL demonstrated in a group of Ital-
ian children [21] and a lower score on the cognitive
scale in Dutch adults [22]. These unexpected normal
scores in most studies may result from the insufficient
sensitivity of the presently available generic HRQoL
measurement tools in detecting the specific problems of
patients with PKU. This is confirmed by the fact that
only a study using a partially validated PKU-specific
questionnaire demonstrated an improvement in patients’
HRQoL after the start of BH4, which allowed relaxation
of the diet in some of the patients [22, 23]. Of note, in
these studies, HRQoL was assessed for about 50 patients
(maximum being 69 in Demirdas et al.), always from
one single country.
In order to evaluate the effectiveness of therapeutic
and supportive interventions for patients with PKU, a
PKU-specific questionnaire is warranted. This paper
aims to describe the HRQoL of a large and international
panel of patients with PKU and their parents via the ad-
ministration of an innovative PKU specific questionnaire.
The conceptual model, plus details of the scaling/scoring




A multicentre, prospective, non-interventional, observa-
tional study was conducted in 34 sites in France,
Germany, Italy, The Netherlands, Spain, Turkey and the
UK from December 2011 to November 2012. The pri-
mary objective of the study was to finalize and validate
the newly developed PKU-specific Quality-of-Life ques-
tionnaire (PKU-QOL). The results related to this pri-
mary objective are reported elsewhere [24].
A secondary objective of the study, which is reported
here, was to describe HRQoL as measured for the first
time by instruments designed to be sensitive to the par-
ticular and sometimes subtle issues characteristic of the
PKU population. As this was the secondary objective,
this paper presents exploratory analyses performed post-
hoc on data collected primarily for the purpose of valid-
ating the PKU-QOL.
Patients included in the study were aged ≥9 years old,
diagnosed with PKU and treated for PKU with a Phe-
restricted diet and/or Phe-free amino acid supplements
(medical food, metabolic formula) and/or pharmaco-
logical therapy. Patients in this study were categorized
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(12–17 years) and Adults (≥18 years). Parents of at least
one patient aged <18 years old treated for PKU with a
Phe-restricted diet and/or Phe-free amino acid supple-
ments and/or pharmacological therapy were also included.
The study was performed in accordance with good
clinical practice and in compliance with local regulatory
requirements. The appropriate national authorities and
institutional review boards approved the protocol before
study commencement. All patients or their legally
authorized representatives provided written informed
consent.
The validation study protocol was submitted to the
Conseil National de l’ordre de Médecins (CNOM) in
France, to the Ethik-Kommission an der Medizinischen
Fakultät der Universität Leipzig, Ethikkommission der
Medizinischen Fakultät Heidelberg, Ethik-Kommission der
MHH, Ethik-Kommission des Fachbereichs Medizin der
Johann Wolfgang Goethe- Universität, Ethik-Kommission
der Ärztekammer Westfalen-Lippe und der medizinischen
Fakultät der Westfälischen Wilhelms Universität Münster
and Ethik-Kommission bei der Landesärztekammer
Baden-Württemberg in Germany, to the Comitato Etico
della Azienda Ospedaliero-Universitaria di Bologna, Comi-
tato Etico per la Sperimentazione Clincal della Provincia
di Vicenza, Comitato Etico per la Sperimentazione della
Azienda Ospedaliera di Padova, Comitato Etico della ASL
NA/1 di Napoli, Comitato di Etica dell ‘IRCCS Istituto
Giannina Gaslini de Genova’ and Comitato Etico Dell
‘Azienda Policlinico Umberto I Di Roma’ in Italy, to the
Academisch Medisch Centrum Amsterdam, Universitair
Medisch Centrum Groningen and Academisch Ziekenhuis
Maastricht (AZM) in the Netherlands, to CCAA Andalu-
cía, CCAA Galicia, CCAA Aragón, CCAA Baleares,
CCAA Pais Vasco and H. Univ Virgen del Rocio in Spain,
to Istanbul University Cerrahpasa Medical Faculty Ethic
Committee in Turkey, to R&D of Glasgow Royal Infirm-
ary, R&D of Central Manchester University Hospitals
NHS Foundation Trust, R&D of University Hospitals Bris-
tol and Guy’s & St Thomas’ Hospital NHS Foundation
Trust in the UK.
Health-Related Quality of life measures
HRQoL was assessed in the study by both generic and
PKU-specific HRQoL measures. The measures were
adapted to the respondent: children and adolescents
completed the Pediatric Quality-of-Life Inventory
(PedsQL) and the Child or Adolescent version of the
PKU-QOL; adult patients completed the Medical Out-
come Survey 36 item Short Form (SF-36) and the Adult
version of the PKU-QOL; and parents of patients with
PKU completed the Child Health Questionnaire 28 item
Parent Form (CHQ-PF28) and the Parent version of the
PKU-QOL.The PKU-QOL is a questionnaire designed to specific-
ally assess the impact of PKU on all aspects of PKU pa-
tients’ life, including: PKU symptoms; the practical,
social and emotional impact of PKU on patient’s life; the
impact of low-protein dietary restrictions; and the im-
pact of Phe-free amino acid supplement intake (add-
itional detail for the questionnaires can be found at
http://www.proqolid.org). It has been developed and val-
idated according to standard methods involving patients’
and clinicians’ input at all stages [24]. It exists in four
versions: three to be completed by patients with PKU
and adapted to their age (Children, Adolescents and
Adults); and one to be completed by parents of patients
with PKU. Depending on the version, the number of
items included in the PKU-QOL ranges between 40
(Child version) and 65 (Adult version), which allow the
assessment of between 28 and 35 domain scores. The
domain scores for each version can be found in Table 1.
PKU-QOL domain scores were interpreted based on the
domain content as follows: scores of <26 indicate little
or no impact (or very limited or no symptoms for symp-
tom scores), scores of >25 and <51 indicate a moderate
impact (or moderate symptoms), scores of >50 and <76
indicate major impact (or severe and/or frequent symp-
tom), scores of >75 indicate severe impact (or very se-
vere and/or very frequent symptoms). Self-rated health
status (a subjective comparison of health with others of
the same age, made by the respondent) was rated as poor
(PKU-QOL score = 4), fair (PKU-QOL score = 3), good
(PKU-QOL score = 2), very good (PKU-QOL score = 1) or
excellent (PKU-QOL score = 0) as part of the Adolescent,
Adult and Parent PKU-QOLs.
The PedsQL is designed to assess HRQoL in children
[25–29]. It is applicable for healthy school and commu-
nity populations, as well as paediatric populations with
acute and chronic health conditions. The PedsQL Gen-
eric Core Scales include 23 items grouped into four do-
mains: Physical Functioning, Emotional Functioning,
Social Functioning, and School Functioning.
The SF-36 is a widely used questionnaire, designed to
measure generic health concepts relevant across adult
age, disease and treatment groups [30–32]. It is a well-
validated measure of general health status and QoL. It
includes eight domains: Physical Functioning, Role-
Physical, Bodily Pain, General Health, Vitality, Social
Functioning, Role-Emotional, and Mental Health. Two
summary scores can be calculated based on the eight do-
main scores: the Standardized Physical Component Scale
and the Standardized Mental Component Scale.
The CHQ is a family of generic QoL questionnaires de-
signed for children and their parents [33, 34]. The 28-item
parent form of the CHQ (CHQ-PF28) contains the follow-
ing domains: Emotional and Time Impact on the Parent,
Limitations in Family Activities and Family Cohesion.
Table 1 PKU-QOL scores in the study samples
PKU-QOL domains – Median (Q1-Q3) Child Sample Adolescent sample Adult sample Parent sample
(N = 92) (N = 110) (N = 104) (N = 253)
Symptoms
Self-rated health status - 50.0 (25.0–50.0) 25.0 (25.0–50.0) -
Child health status - - - 25.0 (0.0–50.0)
Headaches 0.0 (0.0–25.0) 0.0 (0.0–25.0) 25.0 (0.0–50.0) 0.0 (0.0–25.0)
Stomach aches 0.0 (0.0–25.0) 0.0 (0.0–25.0) 0.0 (0.0–25.0) 0.0 (0.0–25.0)
Tiredness 25.0 (25.0–50.0) 50.0 (25.0–50.0) 50.0 (25.0–50.0) 25.0 (0.0–50.0)
Trembling hands - - 0.0 (0.0–25.0) -
Irritability 0.0 (0.0–25.0) 25.0 (0.0–50.0) 25.0 (0.0–50.0) 25.0 (25.0–50.0)
Aggressiveness 0.0 (0.0–25.0) 0.0 (0.0–25.0) 0.0 (0.0–25.0) 0.0 (0.0–25.0)
Moodiness 0.0 (0.0–25.0) 25.0 (0.0–50.0) 25.0 (0.0–50.0) 25.0 (0.0–50.0)
Sadness 0.0 (0.0–25.0) 0.0 (0.0–25.0) 25.0 (0.0–50.0) 25.0 (0.0–25.0)
Anxiety 0.0 (0.0–0.0) 0.0 (0.0–25.0) 0.0 (0.0–50.0) 0.0 (0.0–25.0)
Lack of concentration 0.0 (0.0–25.0)) 0.0 (0.0–25.0) 25.0 (0.0–50.0) 25.0 (0.0–50.0)
Slow thinking 25.0 (0.0–50.0) 0.0 (0.0–25.0) 0.0 (0.0–25.0) 0.0 (0.0–50.0)
PKU in general
Emotional impact of PKU 33.3 (16.7–50.0) 30.0 (20.0–40.0) 45.0 (25.0–60.0) 37.5 (25.0–62.5)
Practical impact of PKU 0.0 (0.0–12.5) 8.3 (0.0–25.0) 12.5 (6.3–25.0) 12.5 (0.0–25.0)
Social impact of PKU 16.7 (8.3–25.0) 16.7 (8.3–25.0) 16.7 (6.3–25.0) 12.5 (5.0–25.0)
Overall impact of PKU 18.8 (12.5–31.3) 20.0 (12.5–30.0) 27.1 (18.8–39.6) 21.4 (11.5–35.0)
Anxiety – blood test 6.3 (0.0–12.5) 0.0 (0.0–12.5) 0.0 (0.0–12.5) 12.5 (0.0–37.5)
Impact of child anxiety – blood test - - - 12.5 (0.0–37.5)
Anxiety – blood Phe levels 50.0 (25.0–75.0) 25.0 (0.0–50.0) 25.0 (25.0–50.0) 50.0 (25.0–75.0)
Anxiety – blood Phe levels during pregnancy - - 100.0 (75.0–100.0)a -
Financial impact of PKU - - 0.0 (0.0–25.0) 25.0 (0.0–50.0)
Information on PKU - - 25.0 (25.0–50.0) 25.0 (0.0–50.0)
Phe-free amino acid supplement administration
Adherence to supplements 0.0 (0.0–12.5) 6.3 (0.0–25.0) 16.7 (0.0–33.3) 0.0 (0.0–25.0)
Management of supplements - - - 0.0 (0.0–25.0)
Practical impact of supplements 0.0 (0.0–25.0) 12.5 (0.0–25.0) 18.8 (6.3–37.5) 8.3 (0.0–33.3)
Guilt if poor adherence to supplements 37.5 (0.0–75.0) 25.0 (25.0–75.0) 50.0 (25.0–75.0) 50.0 (25.0–75.0)
Relationships within family because of supplements 0.0 (0.0–0.0) 0.0 (0.0–25.0) 0.0 (0.0–25.0) 0.0 (0.0–25.0)
Taste – supplements 50.0 (0.0–50.0) 50.0 (25.0–50.0) 50.0 (25.0–50.0) -
Dietary protein restriction
Food temptations 25.0 (0.0–50.0) 25.0 (0.0–50.0) 37.5 (12.5–50.0) -
Adherence to dietary protein restriction 0.0 (0.0–12.5) 8.3 (0.0–18.8) 18.8 (0.0–31.3) 0.0 (0.0–25.0)
Management of dietary protein restriction - - - 20.8 (5.0–37.5)
Social impact of dietary protein restriction 15.0 (5.0–30.0) 5.0 (0.0–20.0) 12.5 (4.2–25.0) -
Practical impact of dietary protein restriction - 28.6 (14.3–32.1) 35.0 (20.8–50.0) 28.6 (14.3–46.4)
Overall impact of dietary protein restriction - 17.8 (9.1–25.0) 25.0 (11.5–37.5) -
Taste – specialty low protein food 25.0 (0.0–25.0) 25.0 (0.0–37.5) 25.0 (25.0–50.0) -
Food enjoyment 0.0 (0.0–25.0) 0.0 (0.0–25.0) 25.0 (0.0–50.0) 25.0 (0.0–25.0)
Guilt if dietary protein restriction not followed 50.0 (0.0–100.0) 50.0 (25.0–75.0) 50.0 (25.0–75.0) 50.0 (25.0–75.0)
Overall difficulty following dietary protein restriction 0.0 (0.0–25.0) 0.0 (0.0–25.0) 25.0 (0.0–50.0) -
Note: lower PKU-QOL scores represent more positive outcome; 0 (no impact/no symptom) and 100 (extremely severe impact/very frequent symptom)
aFemale patients only, n = 66
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HRQoL domain scores were computed for both generic
and PKU-specific HRQoL measures in each group (Chil-
dren, Adolescent, Adults, Parents). Mean generic do-
main scores obtained in this study were interpreted in
light of reference values from published general popula-
tion samples for the PedsQL [35], the SF-36 [36] and the
CHQ-PF28 [37]. Reference values from the US popula-
tion were used despite the European nature of our sam-
ple because they were the only ones consistently
available from large samples for all questionnaires. Me-
dian and interquartile range for PKU-QOL scores are re-
ported throughout the manuscript to take into account
some skewed distributions. Means were also computed
for consistency with the scores from the generic instru-
ments, and are reported in the supplementary materials.
PKU-QOL domain scores were then compared be-
tween different subgroups of patients defined according
to severity of PKU (defined as mild/moderate [Phe level
at diagnosis 600–1200 μmol/L] vs. classical [Phe level at
diagnosis >1200 μmol/L]); overall assessment of patient’s
health status as rated by the investigator (i.e., response
to the question: “In general, how would you rate the
overall health status of your patient?” Poor/Fair/Good/
Very good/Excellent), and treatment with tetrahydro-
biopterin (BH4).
These analyses were secondary analyses of data col-
lected using the PKU-QOL under validation so the sam-
ple size of the study was not specifically determined for
the results presented here. Also, given the descriptive
and explanatory nature of these analyses, no adjustment
for multiple testing has been applied, and the p-values




Of the 617 subjects recruited in the study, 559 returned
a PKU-QOL and were used in the analyses: 306 patients
with PKU and 253 parents of patients with PKU. The
patient sample included 92 children aged 9–11 years,
110 adolescents aged 12–17 years and 104 adults older
than 18 years of age. The parent sample included the
parents of 201 subjects from the child or adolescent
sample, and 52 additional parents of children younger
than eight years old.
Detailed demographic and clinical characteristics of
the samples are provided in Table 2. Clinician overall as-
sessment of patient’s health status ranged from good to
excellent for almost all subjects across all samples. The
distribution between male and female subjects was bal-
anced in all study groups, except in the Adult and Parent
samples, where the percentage of female subjects was
higher. More than six out of 10 subjects had a classicalPKU at the time of diagnosis (Phe level >1200 μmol/L).
Almost half of the patients (43.5%) only had a medical
follow-up (i.e., a follow-up by a GP, paediatrician, endo-
crinologist, and/or specialized nurse) and 31.7% were
followed by a dietician/nutritionist in addition to the
medical team. In subjects following a pharmacological
treatment, BH4 appeared to be the only pharmacological
treatment reported for a substantial proportion of pa-
tients (14–29%, depending on the sample).
Description of Health-Related Quality of life of
PKU patients
HRQoL assessed by generic questionnaires
Scores of the generic QOL instruments, PedsQL, SF-36
and CHQ-PF28 administered to children and adoles-
cents, adults and parents, respectively, are presented in
Table 3. All PedsQL scores of children and adolescents
with PKU were in the same range (±3points) as those
observed in a large health survey conducted in US chil-
dren aged 8 to 16 years [35], except the Social function-
ing score which was 7.9 points higher in our sample. In
the sample of adults with PKU, SF-36 scores pertaining
to the physical domains (Physical functioning, Role-
Physical, Bodily Pain, standardized physical component)
were higher than those observed in a large survey con-
ducted in the US general population while the observed
mean scores pertaining to mental domains (Mental
Health, Role-Emotional, standardized Mental Component)
were consistently slightly lower. The largest difference for
the SF-36 was observed for Physical functioning for which
adults with PKU reported a higher score (95.0 ± 10.2) than
the general US population (80.6 ± 25.1), suggesting phys-
ical functioning is less impacted in these patients than in
the general US population. Most CHQ-PF28 scores ob-
served in parents of children and adolescents with PKU
were very similar (± 3.5 points) to those reported by a
general US population sample. The only CHQ-PF28 do-
main score with a larger difference was Emotional Paren-
tal impact for which parents of children with PKU
reported a 10.9 point lower score (70.4 ± 28.8) than the
general US population (81.3 ± 18.4), suggesting a greater
emotional impact in these parents than in the general US
population.
HRQoL assessed by the PKU-QOL
PKU-QOL scores for each sample are presented in
Table 1. Overall, adolescents and adults rated their over-
all health status as good (38.2% and 40.4% of patients,
respectively) or very good (23.6% and 30.8% of patients,
respectively), compared with others of their age. A simi-
lar finding was also made in parents reporting on the
health status of their child. For all age groups, the high-
est observed median symptom score for self-reported
patient versions was for tiredness (25.0 [25.0–50.0] in










sampleb (N = 52)
Age (years) n (missing) 90 (2) 110 (0) 101 (3) 244 (9) 52 (0)
Mean (SD) 9.8 (0.8) 14.5 (1.6) 25.8 (6.6) 41.6 (6.5) 4.4 (2.5)
Min – Max 9.0–11.0 12.0–17.0 18.0–45.0 24.0–66.0 0.0–8.0
Gender Male 43 (46.7) 56 (50.9) 38 (36.5) 69 (27.3) 28 (53.8)
n (%)
Female 47 (51.1) 54 (49.1) 66 (63.5) 183 (72.3) 24 (46.2)
Missing 2 (2.2) 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0)
Treated with BH4 n (%) 27 (29.3) 27 (24.5) 15 (14.4) – 13 (25.0)
PKU severity Classicalc 66 (71.7) 75 (68.2) 67(64.4) – 32 (61.5)
n (%) Missing 4 (4.3) 2 (1.8) 0 (0.0) – 0 (0.0)
Management Medical only 45 (48.9) 49 (44.5) 39 (37.5) – 21 (40.4)
n (%) Multi-disciplinary
team
45 (48.9) 61 (55.5) 63 (60.6) – 31 (59.6)
Missing 2 (2.2) 0 (0.0) 0 (0.0) – 0 (0.0)
Overall health status rating
by clinician
Poor 0 (0.0) 0 (0.0) 0 (0.0) – 0 (0.0)
Fair 2 (2.1) 0 (0.0) 3 (2.9) – 0 (0.0)
n (%)
Good 19 (20.7) 38 (34.5) 28 (26.9) – 7 (13.5)
Very good 41 (44.6) 42 (38.2) 46 (44.2) – 18 (34.6)
Excellent 28 (30.4) 30 (27.3) 26 (25.0) – 27 (51.9)
Missing 2 (2.2) 0 (0.0) 1 (1.0) – 0 (0.0)
Country France 13 (14.1) 10 (9.1) 18 (17.3) 33 (13.0) 10 (19.2)
n (%) Germany 19 (20.7) 20 (18.2) 21 (20.2) 46 (18.2) 8 (15.4)
Italy 15 (16.3) 26 (23.6) 22 (21.2) 49 (19.4) 8 (15.4)
Netherlands 7 (7.6) 10 (9.1) 7 (6.7) 23 (9.1) 6 (11.5)
Spain 20 (21.7) 20 (18.2) 21 (20.2) 48 (19.0) 8 (15.4)
Turkey 14 (15.2) 20 (18.2) 8 (7.7) 40 (15.8) 6 (11.5)
UK 4 (4.3) 4 (3.6) 7 (6.7) 14 (5.5) 6 (11.5)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
SD standard deviation
aData for the Parent sample relate to the parent and not the children; hence characteristics related to disease are not reported
bChildren with PKU younger than eight years old for whom a parent-completed PKU-QOL was collected
cClassical PKU defined as Phe level at diagnosis >1200 μmol/L
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[25.0–50.0] in the Adult versions – all indicating mod-
erate symptoms). The observed median tiredness score
in the Parent version reporting about their child’s
HRQoL (25.0 [0.0–50.0]) was just below the score indi-
cating moderate symptoms. For the Parent version, the
median symptom scores for child health status (25.0
[0.0–50.0]), irritability (25.0 [25.0–50.0]), moodiness
(25.0 [0.0–50.0]), sadness (25.0 [0.0–25.0]) and lack of
concentration (25.0 [0.0–50.0]) also fell just short of
the score interpreted as indicating a moderate level of
symptoms.The highest PKU-QOL impact scores were the ones
measuring the emotional impact of PKU and its man-
agement (emotional impact of PKU, anxiety about blood
Phe levels, guilt related to poor adherence to dietary re-
strictions or Phe-free amino acid supplement intake).
The highest median score (i.e., the highest impact of
PKU), across all scores from all versions, was for the
score measuring anxiety regarding blood Phe levels dur-
ing pregnancy in the Adult version of the PKU question-
naire with a median score of 100.0 (75.0–100.0).
In all patient versions, the score assessing the impact
of the taste of Phe-free amino acid supplements was also
Table 3 Scores from generic QOL instruments (PedsQL, SF-36 and CHQ-PF28) in the study samples and in the US general population
Generic QOL instruments Study samples US normative data samples
PedsQL scores – Mean (SD) Child Sample (N = 92) (N = 5972)a
Physical functioning score 88.9 (10.7) 86.9 (13.9)
Emotional functioning score 78.8 (16.9) 78.2 (18.6)
Social functioning score 91.9 (12.6) 84.0 (17.0)
School functioning score 80.3 (14.0) 80.0 (17.0)
Psychosocial health summary score 83.7 (11.1) 80.7 (14.7)
PedsQL total scale score 85.5 (9.8) 82.9 (13.2)
PedsQL scores – Mean (SD) Adolescent Sample (N = 110) (N = 5972)a
Physical functioning score 88.8 (11.1) 86.9 (13.9)
Emotional functioning score 81.0 (16.2) 78.2 (18.6)
Social functioning score 90.9 (14.0) 84.0 (17.0)
School functioning score 77.1 (15.6) 80.0 (17.0)
Psychosocial health summary score 83.1 (11.9) 80.7 (14.7)
PedsQL total scale score 85.1 (10.5) 82.9 (13.2)
SF-36 scores – Mean (SD) Adult Sample (N = 104) (N = 7069)b
Physical Functioning 95.0 (10.2) 80.6 (25.1)
Role-Physical 86.2 (19.3) 80.8 (25.5)
General Health 77.8 (18.2) 70.1 (21.3)
Bodily Pain 83.9 (20.5) 70.1 (24.3)
Role-Emotional 83.3 (22.6) 86.3 (22.5)
Mental Health 71.8 (19.1) 75.2 (18.4)
Vitality 61.7 (19.1) 58.8 (20.7)
Social Functioning 84.4 (21.5) 83.7 (23.6)
Mental Component Scale 46.8 (10.8) 49.9 (10.1)
Physical Component Scale 55.9 (5.5) 50.0 (10.0)
CHQ-PF28 – Mean (SD) Parent Sample (N = 253) (N = 391)c
Physical Functioning 95.3 (14.3) 95.0 (16.2)
Role/Social Limitations – Physical 96.1 (14.4) 93.7 (19.7)
General Health Perceptions 70.5 (17.6) 74.0 (19.8)
Bodily Pain/Discomfort 83.0 (18.8) 81.3 (19.7)
Parental Impact – Time 87.9 (21.3) 88.4 (20.9)
Parental Impact – Emotional 70.4 (28.8) 81.3 (18.4)
Role/Social Limitations – Emotional/Behavioral 90.9 (21.3) 92.5 (19.1)
Self Esteem 79.4 (19.1) 80.1 (19.1)
Mental Health 77.0 (19.0) 79.7 (15.5)
Behavior 73.1 (18.9) 70.8 (18.7)
Family Activities 88.3 (19.7) 91.1 (18.9)
Family Cohesion 72.5 (22.2) 72.4 (21.6)
Physical Summary Score 53.0 (7.8) 53.2 (9.5)
Psychosocial Summary Score 49.3 (10.6) 51.1 (9.6)
SD standard deviation, PedsQL pediatric quality of life inventory, SF-36 36-item short form, CHQ-PF28 child health questionnaire parent form 28 items, US
United States
Note: higher scores represent more positive outcome for each instrument
aData from Varni et al. 2003 [35]
bData from Ware et al. 2007 [36]
cData from HealthActCHQ. 2008 [37]
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taste acceptance for these products (50.0 [0.0–50.0] in
the Child, 50.0 [25.0–50.0] in the Adolescent and 50.0
[25.0–50.0] in the Adult versions).
PKU-QOL scores between subgroups of patients
PKU-QOL scores according to severity of PKU
All comparisons of PKU-QOL scores for subgroups
based on the severity of PKU (as defined by blood Phe
level at diagnosis) are reported in Additional file 1: Table
S1. No clear association between the symptoms of PKU
and the severity of PKU were observed. A consistent
pattern emerged regarding the impact of Phe-free amino
acid supplement intake according to the severity of PKU
(Fig. 1): patients with classical PKU, in particular adoles-
cents and children, reported a slightly greater impact of
Phe-free amino acid supplements on practical and emo-
tional (guilt related to poor adherence) domains.
An association was also found in adolescents between
the impact of dietary restriction and the severity of PKU:
adolescents with classical PKU reported a slightly poorer
adherence to their diet and higher impact (social and
emotional) (Additional file 1: Table S1). This finding was
not replicated in adults. In children, the findings variedFig. 1 Comparison of PKU-QOL scores related to Phe-free amino acid supp
600–1200 μmol/L; Classical PKU: Phe level >1200 μmol/L) in children (N = 9
Box-plots presents the following: interquartile range (Q1-Q3); +: mean; –: m
observed values; ○: outliers (i.e., values that are outside the distance of 1.5according to the respondents: the impact of the diet
measured by the self-reported Child version did not dif-
fer according to the severity of PKU, whilst results from
the Parent version showed children with classical PKU
as having poorer dietary adherence and experiencing
greater impact from the diet than children with mild or
moderate PKU (Additional file 1: Table S1).
PKU-QOL scores according to overall health status
All comparisons related to the overall health status as
assessed by the clinicians are reported in the Additional
file 2: Table S2. Overall, patients with better health sta-
tus according to the clinicians’ global rating tended to
have lower symptom scores (i.e., less frequent symp-
toms) and lower PKU impact scores, particularly in
Adult and Parent questionnaires. No patients’ health sta-
tus was reported as “Poor” by their clinician, and very
few as “Fair”; this reflects the overall good health status
of patients with PKU, with very few having a health sta-
tus rated as worse than “Good”.
No clear association was found between patients’
health status as assessed by the clinician and the impact
of the Phe-free amino acid supplement administration
or the dietary protein restriction scores.lements according to PKU severity (mild/moderate PKU: Phe level
2), adolescents (N = 110), parents (N = 253) and adults (N = 104).
edian; bottom and top bars: observed minimum and maximum
times the interquartile range from Q1 or Q3)
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All BH4 intake-related comparisons are reported in Add-
itional file 3: Table S3. Consistently for all groups the
practical impact of Phe-free amino-acid supplement was
lower in patients treated by BH4 than those with no BH4
intake who were treated with diet only, and for all PKU-
QOLs except the Child version there was better adher-
ence to Phe-free amino-acid supplement administration
in patients treated by BH4 (Fig. 2 and Additional file 3:
Table S3). The impact of the dietary restriction (overall
impact as well as social and practical impact) was lower
in adolescent and adult patients receiving pharmaco-
logical treatment with BH4 compared to patients not
treated with BH4 (Fig. 3). Very little difference in PKU-
QOL symptoms and PKU impact scores was observed
between patients taking BH4 and those who did not.
Discussion
This is the first study to investigate the HRQoL of a
large international sample of patients with PKU using
the PKU-QOL, a recently developed PKU-specific HRQoL
questionnaire, as well as generic questionnaires. A total of
306 patients and 253 parents from seven countries partici-
pated in the study. This paper presents exploratory analysesFig. 2 Comparison of PKU-QOL scores related to Phe-free amino acid supp
(N = 110), parents (N = 253) and adults (N = 104). Box-plots presents the foll
top bars: observed minimum and maximum observed values; ○: outliers (i.e
range from Q1 or Q3)performed post-hoc on data collected primarily for the pur-
pose of validating the PKU-QOL, reflecting the secondary
objective of describing HRQoL measured by instruments
specifically designed to address issues characteristic of the
PKU population. Because of the exploratory nature of this
aspect of the research, caution has been used in interpret-
ing the findings.
HRQoL of PKU patients: generic questionnaires
All patients and parents completed age-specific generic
HRQoL questionnaires (PedsQL, Child Health Question-
naire PF28, SF36). The children and adolescents re-
ported PedsQL scores comparable to the US normative
data sample, confirming previous study reports of con-
sistently normal scores on generic questionnaires in pa-
tients with PKU [17–20]. On the SF36 questionnaire the
adult group presented higher mean scores on the phys-
ical domains, but slightly lower mean scores on the
mental domains compared to the US norm scores.
Higher physical scores have been reported before by pa-
tients with PKU [22] and may be attributed to the fact
that adult patients included in PKU studies are likely to
be younger than adults in the reference group from the
general populations – the mean age of adults recruitedlements according to BH4 intake in children (N = 92), adolescents
owing: interquartile range (Q1-Q3); +: mean; –: median; bottom and
., values that are outside the distance of 1.5 times the interquartile
Fig. 3 Comparison of PKU-QOL scores related to diet according to BH4 intake in children (N = 92), adolescents (N = 110), parents (N = 253) and
adults (N = 104). Box-plots presents the following: interquartile range (Q1-Q3); +: mean; –: median; bottom and top bars: observed minimum and
maximum observed values; ○: outliers (i.e., values that are outside the distance of 1.5 times the interquartile range from Q1 or Q3)
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the sample for the general population completing the
SF-36 [36]. Alternatively this may also be because of a
response shift: PKU patients grow up with the know-
ledge that poor adherence with dietary treatment may
harm their health and abilities, and they may appreciate
their own health more than the general population,
possibly resulting in higher HRQoL scores [22]. Lower
mental scores on generic questionnaires have been pre-
viously reported in PKU adults as well and may result
from the lower mean IQ found in patients with PKU or
from the negative effects of high blood Phe levels on ex-
ecutive function and mood [12–16, 22].
Parents reported scores on the CHQ-PF28 comparable
to the US norms, except for a lower score on the emo-
tional parental impact domain, indicating a higher
emotional impact than the general population. Consider-
ing the severity of disease and burden of treatment this
is an expected outcome, which confirms previous studies
reporting parental fears of school failure [20] and normal
overall parental QoL, but with an increased vulnerability
of parents of younger children [38]. It has been demon-
strated that family stress, perceived limited social support
and loss of friendship are the most powerful predictors of
lower HRQoL in parents of PKU patients [16, 38].HRQoL of PKU patients: PKU-specific questionnaire
The PKU-QOL addresses PKU specific issues such as
PKU symptoms, impact of PKU and its management,
dietary protein restriction and administration of Phe-free
amino acid supplements. Patients of all ages gave highest
scores to domains addressing the emotional impact of
PKU and the management of PKU, including anxiety
about high blood Phe levels and guilt related to poor ad-
herence to dietary restrictions or supplement intake.
The highest score in females in all patient groups was
the score measuring anxiety regarding high blood Phe
levels during pregnancy, which demonstrates that female
patients are well aware of the risks to the foetus in an
unplanned pregnancy [39].
Because the questionnaire addresses issues relevant
only to PKU patients and their parents, it is not possible
to compare scores to a control group from a general
population. However, a comparison between patient
groups was possible and allowed confirmation that these
questionnaires are sensitive to HRQoL issues character-
istic of the PKU populations, although further study will
be necessary to confirm that they can demonstrate the
effects of supportive interventions (such as referral to
and support by a psychologist, improvement of know-
ledge through PKU camps, etc.), of treatment differences
Bosch et al. Orphanet Journal of Rare Diseases  (2015) 10:80 Page 11 of 14(such as BH4 versus diet only) and of future treatment
tools.
Effects of severity of PKU
In PKU patients a major determinant for the burden of
disease is disease severity, which determines tolerance to
dietary Phe. Those patients with lower Phe tolerance ne-
cessarily require a more severe dietary protein restriction
to maintain blood Phe within recommended ranges.
The severity of protein restriction thus significantly af-
fects adherence difficulty and quality of life. A commonly
used severity classification for PKU is by blood Phe
level at the time of diagnosis, with a Phe level of >1200
μmol/L classifying as severe (classical) PKU and a Phe
level <1200 μmol/L as mild to moderate PKU. Due to
the high overall scores on generic HRQoL question-
naires, previous studies could not demonstrate the clin-
ically observed differences in HRQoL between these
groups. Therefore, we evaluated differences in PKU-
QOL scores between patients with mild-moderate and
severe PKU. In this study more than two-thirds of the
patients evaluated (68%) had classic PKU and this pro-
portion was fairly stable across all age groups, although
slightly higher in children (71%).
The differences in HRQoL between patients with
mild-moderate and severe PKU observed in all age
groups made sense from a clinical perspective. In the
mild-moderate PKU group adolescents reported better
health status and fewer mood swings, and adults and ad-
olescents demonstrated a trend to lower emotional,
practical, social and overall impact of PKU, compared to
those with severe PKU. Also, adults demonstrated a
trend to lower financial impact of PKU with less severe
disease. Parents of mild-moderate patients reported
lower practical, financial, and overall impact of PKU,
and a trend for a lower emotional impact than parents
of patients with severe PKU.
In the domain of dietary impact, adolescents with se-
vere PKU reported higher overall impact of the diet
(both social and practical impact), more guilt if the diet
is not followed, less food enjoyment and trends for more
food temptation than adolescents with mild-moderate
disease. Parents of patients with severe PKU reported
less food enjoyment and poorer adherence to diet, as
well as trends for more difficulty with diet management,
more practical impact and more guilt if the diet is not
followed than parents with less severe PKU.
Remarkably these differences in the diet domain are
not seen in the adult sample. This may result from
higher accepted treatment blood Phe ranges in adults
compared to children and adolescents in many coun-
tries, thus allowing a more relaxed diet restriction [1].
Furthermore, parents enforce adherence during childhood
because they understand dietary treatment is importantfor good outcome, and fear possible long term effects of
higher blood Phe. During adolescence acceptance of the
importance of dietary therapy conflicts with fear of being
different because of the diet, and becomes a major
HRQoL issue.
This study clearly demonstrates that severity of PKU is
negatively associated with the patients’ HRQoL and that
treatment options enabling relaxation of diet may im-
prove HRQoL as measured with a PKU-specific ques-
tionnaire. At this time the only pharmacological
treatment for PKU is BH4 (combined with diet therapy)
which may increase Phe tolerance in patients who are
responsive. These patients may be able to considerably
relax dietary Phe restrictions, include more natural pro-
tein in their diet, and/or decrease Phe-free amino acid
supplement intake.
Effects of BH4 treatment
Previous studies evaluating the effects of BH4 treatment
with generic HRQoL questionnaires were not able to
demonstrate any of the striking beneficial effects clinic-
ally observed by professionals and patients [22, 40].
Therefore the cohort of patients receiving BH4 treat-
ment (n = 69), in addition to dietary therapy and Phe-
free amino acid supplement (except in very rare cases),
was compared to the cohort of patients treated with diet
and Phe-free amino acid supplement only (237). In the
domain of PKU symptoms, adolescents treated with BH4
reported less sadness than patients not receiving BH4,
while adults receiving BH4 presented a trend of less ag-
gressiveness and less slow thinking. This could result
from lower blood Phe values in patients treated with
BH4, as higher blood Phe values are associated with
mood disturbances and a lower sustained attention. Re-
markably, parents of children treated with BH4 reported
more mood swings. Compared to adolescents and adults
treated with diet only, adolescents and adults receiving
BH4 reported less food temptation and a lesser social
impact of dietary restriction (feeling different because of
diet, conflict with parents about diet, difficulty watching
others eat, feeling socially restricted because of diet). In
adults the overall impact of diet (social impact plus prac-
tical difficulties such as difficulty eating out, need to plan
the meals in advance, time needed to prepare the meals)
was lower in patients treated with BH4. Also, the domain
“overall difficulty of the diet” (a single item score meas-
uring the perceived difficulty of following the diet) pre-
sented lower scores in adolescents and a beneficial trend
in adults receiving BH4. A lower financial impact was
also reported by PKU adults receiving BH4.
Importantly, parents reported a better adherence to
diet in children receiving BH4.
Children receiving BH4 treatment exhibited less guilt
related to poor adherence to Phe-free supplement intake,
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practical impact of Phe-free amino acid supplement ad-
ministration. Adolescents, adults and parents reported a
slightly better adherence to Phe-free amino acid supple-
ment intake.
BH4 treatment is associated with better scores on the
domains of the PKU-specific questionnaire in all ages and
these results confirm the clinical observation that a less
restricted diet and lower Phe-free amino acid supplement
intake, often allowed by response to BH4, will positively
affect the HRQoL of the patients. The higher score on
mood swing in children using BH4 is as yet unexplained
and future studies will need to address this finding.
The fact that the PKU-QOL questionnaires may allow
description of differences in HRQoL between patients
with differing severity of PKU, and patients receiving dif-
ferent treatment modalities confirms the usefulness of the
instrument. The PKU-QOL is anticipated to become a
valuable tool in the evaluation and care of patients with
PKU, as well in understanding and documenting quality of
life concerns specific to and characteristic of the PKU
population.
Limitations of the study
Patients and parents from seven countries participated in
the study. Hence cross-cultural differences in HRQoL
may exist, in particular due to differences in access to
different treatment options. Differences in impact on
HRQoL depending on treatment have been evaluated but,
due to the small sample size in each country, these ana-
lyses could not be conducted at the country level. The
scores on the generic questionnaires have been compared
to the USA norm group, as norm scores were not available
for the participating countries. This introduces a potential
bias in terms of the matching of the demographics, culture
and behaviour of the two groups. However, it was consid-
ered useful for the interpretation of results to have a refer-
ence, and as our cohort is the largest and internationally
most diverse cohort of PKU patients ever evaluated for
HRQoL, the US norm scores can be expected to be based
on a comparable diversity. Furthermore, results clearly
confirm previous findings in studies using national norm
scores [17, 19, 20, 22, 40].
A larger sample size would have allowed more in-depth
analysis; however the sample included was relatively large
for this rare condition (we believe it was the largest cohort
of PKU patients ever evaluated for HRQoL), and allowed
the primary objective of the study – validation of the fu-
ture usefulness of the instruments – to be achieved.
Finally, it is important to note that this analysis is ex-
ploratory by nature (it was performed to support a
secondary objective of the study and involves a large num-
ber of statistical tests) and its results should be interpreted
as such. In particular, all the findings resulting from thecomparisons of PKU-QOL scores should be considered
cautiously and would need to be confirmed in further
studies. One of the main findings was the potential allevi-
ation of the negative impact of diet restriction and Phe-
free amino acid supplement intake in patients who were
treated with BH4, which is suggested by our results. How-
ever, one of the questions related to this finding is whether
this could be explained by a difference in PKU severity in
patients treated with BH4. Patients with mild/moderate
PKU are more likely to respond to BH4, which is con-
firmed in our sample (across all age groups, there were
consistently more than 60% of the patients receiving BH4
who had mild/moderate PKU while they were fewer than
30% of patients not receiving BH4). So PKU severity may
be a confounding factor in the association between PKU-
QOL scores and BH4 intake; however, given the relatively
small number of patients who were receiving BH4 in the
sample, a subgroup analysis of this sample according to
PKU severity was not possible. This important question
should be further explored in future research.Use of the PKU-QOL
The PKU-QOL is now available in seven languages and
has been demonstrated to be valid for use in France,
Germany, Italy, The Netherlands, Spain, Turkey and the
UK. It is a valid and reliable measure of the multifaceted
impact of PKU on patients of different age groups (chil-
dren, adolescents and adults) and their parents [24]. In
the large cohort of patients and parents involved in the
development and validation of the instrument, clinically
observed differences were clearly and consistently reflected
in the score differences between mild-moderate and severe
patients; and in patients receiving different treatments,
supporting the validity of the questionnaire. While the
questionnaire was primarily developed to be used in the
context of clinical research, it could also be a powerful tool
in the context of patient care and follow-up.
In research, the PKU-QOL could be a valuable asset in
studies evaluating interventions (such as educational
programs and psychosocial referrals) as well as new
treatment options, with repeated measurements over
time.
In patient care, the questionnaire could be useful to
provide the clinician with a standardized picture of their
patient’s perspective. The use of questionnaires has been
evaluated in many different chronic disorders and has
been demonstrated to significantly increase dialogue on
psychosocial function and emotional function in cohorts
of adults and children with cancer, and to improve psy-
chosocial outcome in children and adolescents with dia-
betes and adults with cancer [41–44]. An individual
patient’s HRQoL can be followed over time, as well as be-
fore and after individual interventions (such as changes in
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the patient serves as his/her own control.
Values generated in this large sample and provided in
this paper could be used as helpful references. However
this does present a risk of bias, and cultural differences as
well as treatment severity must be taken into account. For
this reason, different reference scores are provided for
mild-moderate and severe PKU patients. In particular,
BH4-responsive patients who may tolerate less dietary
restriction might be compared to the mild-moderate
patients.Conclusions
Overall, patients with PKU showed good HRQoL, both
with the generic and PKU-specific measures. Nonetheless,
a negative impact of PKU on a patient’s life, in particular
the emotional impact of PKU and its management, was de-
lineated by the PKU-QOLs across all age groups. Patients
with milder PKU and patients treated with BH4 reported a
lower impact of dietary restriction and Phe-free amino acid
supplement intake (social and practical), reflecting the re-
laxed constraints in these patients. These results support
the ability of the PKU-QOL to identify HRQoL issues char-
acteristic of the PKU population, and to measure HRQoL
differences specific to severity of disease and treatment re-
ceived. Further research is now needed to gain a better un-
derstanding of the effect of present and future PKU
treatments on patient-centred outcomes, in particular in
longitudinal studies that would allow the assessment of
treatment effects over time.Intellectual property and condition of use
The PKU-QOLs are protected by international copyright –
PKU-QOL © Merck Serono S.A. - Geneva – 2010-
The PKU-QOL is available freely for use in individual
medical practice and in non-privately funded academic
research. Access to the questionnaire, as well as further in-
formation on, or permission to use the PKU-QOL and/or
its translations, can be found on http://www.proqolid.orgAdditional files
Additional file 1: Table S1. Comparisons of PKU-QOL scores according
to the severity of PKU. This file includes four tables presenting in the
child, adolescent, adult and parent samples the comparison of PKU-QOL
scores according to the severity of PKU (mild-moderate PKU: Phe level
600–1200 μmol/L; Classical PKU: Phe level >1200 μmol/L).
Additional file 2: Table S2. Comparisons of PKU-QOL scores according
to the overall health status as assessed by the clinicians. This file includes
four tables presenting in the child, adolescent, adult and parent samples
the comparison of PKU-QOL scores according to the overall assessment
of health status made by the clinicians (poor; fair; good; very good;
excellent).
Additional file 3: Table S3. Comparisons of PKU-QOL scores according
to BH4 intake. This file includes four tables presenting in the child,adolescent, adult and parent samples the comparison of PKU-QOL scores
according to BH4 intake (BH4 intake; no BH4 intake).Abbreviations
BH4: Tetrahydrobiopterin; CHQ-PF: Child Health Questionnaire–Parent Form;
PedsQL: Pediatric Quality-of-Life Inventory; Phe: Phenylalanine;
PKU: Phenylketonuria; PKU-QOL: PKU-specific Quality of Life questionnaire;
HRQoL: Health-Related Quality of Life; SF-36: Medical Outcome Survey
36-item Short Form.
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